Similar articles

• [Aldose reductase inhibitors in diabetic neuropathy].

  Erkelens DW, Bravenboer B. Erkelens DW, et al. Ned Tijdschr Geneeskd. 1990 Apr 14;134(15):775-6. Ned Tijdschr Geneeskd. 1990. PMID: 2110629 Dutch. No abstract available.
• Inhibition of aldehyde reductase by aldose reductase inhibitors.

  Sato S, Kador PF. Sato S, et al. Biochem Pharmacol. 1990 Sep 1;40(5):1033-42. doi: 10.1016/0006-2952(90)90490-c. Biochem Pharmacol. 1990. PMID: 2117925
• Aldose reductase inhibitors: a potential new class of agents for the pharmacological control of certain diabetic complications.

  Kador PF, Kinoshita JH, Sharpless NE. Kador PF, et al. J Med Chem. 1985 Jul;28(7):841-9. doi: 10.1021/jm00145a001. J Med Chem. 1985. PMID: 3925146 Review. No abstract available.
• Effects of an aldose reductase inhibitor, 1-[(p-bromophenyl)-sulfonyl]hydantoin, on cataract formation and tissue polyol levels in galactosemic rats.

  Okuda J, Yashima K, Inagaki K, Miwa I. Okuda J, et al. Chem Pharm Bull (Tokyo). 1985 Jul;33(7):2990-5. doi: 10.1248/cpb.33.2990. Chem Pharm Bull (Tokyo). 1985. PMID: 3936627 No abstract available.
• Medicinal chemistry of aldose reductase inhibitors.

  Larson ER, Lipinski CA, Sarges R. Larson ER, et al. Med Res Rev. 1988 Apr-Jun;8(2):159-86. doi: 10.1002/med.2610080202. Med Res Rev. 1988. PMID: 3132580 Review. No abstract available.